Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs

Archives of General Psychiatry

Volumn 45, Issue 1, 1988, Pages 71-76

  Farde, Lars ^a   Wiesel, Fritz Axel ^a   Halldin, Christer ^b   Sedvall, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; SULPIRIDE;

ADULT; CLINICAL ARTICLE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CARBON RADIOISOTOPES; COMPARATIVE STUDY; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMAN; MALE; MIDDLE AGE; NORTRIPTYLINE; PUTAMEN; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SULPIRIDE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0023853769     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1988.01800250087012     Document Type: Article

References (40)

1. Delay J, Deniker O: Caracteristiques psycho-physioloques des medicaments neuroleptiques, in Garattini S, Ghetti V (eds): The Psychotropic Drugs. Amsterdam, Elsevier Science Publishers, 1957, pp 485-501.
2. Klein D, Davis J: Diagnosis and Drug Treatment of Psychiatric Disorders. Baltimore, Williams & Wilkins, 1962.
3. Wiesel F-A, Alfredsson G, Likwornik V, Sedvall G: A relation between drug concentrations in brain and striatal homovanillic acid levels in chlorpromazine treated rats. Life Sci 1975;16:1145-1156.
4. Dahl S: Plasma level monitoring of antipsychotic drugs: Clinical utility. Clin Pharmacokinet 1986;11:36-61.
5. Carlsson A, Lindqvist M: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140-144.
6. Carlsson A: Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 1978;135:164-173.
7. Creese I, Burt DR, Snyder SH: Dopamine receptor binding clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
8. Seeman P, Lee T, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719.
9. Peroutka SJ, Snyder SH: Relationship of neuroleptic drug effects at brain dopamine, serotonin, adrenergic and histamine receptors to clinical potency. Am J Psychiatry 1980;137:1518-1522.
10. Wagner HN, Burns HD, Dannals RF, Wong DF, Långström B, Duelfer T, Frost JJ, Raert HT, Links JM, Rosenblom SB, Lukas SE, Kramer AV, Kuhar MJ: Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:1264-1266.
11. Maziere B, Loc'h C, Baron J-C, Sgouropoulos P, Duquesnoy N, D'Antona R, Cambon H: In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and (76Br) bromospiperone. Eur J Pharmacol 1985;114:276-272.
12. Farde L, Wiesel F-A, Ehrin E, Hall H, Sedvall G: Quantitative PET-scan determination of dopamine-D2 receptor binding in schizophrenic patients treated with distinct classes of antipsychotic drugs, in Shagass C (ed): Biol Psychiatry 1985;7:363-365.
13. Farde L, Hall H, Ehrin E, Sedvall G: Quantitative analysis of dopamine-D2 receptor binding in the living human brain by positron emission tomography. Science 1986;231:258-261.
14. Sedvall G, Farde L, Persson A, Wiesel F-A: Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry 1986;43:995-1005.
15. Farde L, Ehrin E, Eriksson L, Greitz TY, Hall H, Hedström CG, Litton JE, Sedvall G: Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 1985;82:3863-3867.
16. Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S, Sedvall G: No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987;44:671-672.
17. Bergström M, Boethius J, Eriksson L, Greitz T, Ribbe T, Widen L: Head fixation device for reproducible positron alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 1981;8:74-87.
18. Cheng Y, Prusoff W: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
19. Alfredsson G, Sedvall G, Wiesel F-A: Quantitative analysis of sulpiride in body fluids by high performance liquid chromatography with fluorescence detection. J Chromatogr 1979;164:187-193.
20. Larsson M, Forsman A, Öhman R: A high-performance liquid chromatographic method for the determination of haloperidol and reduced haloperidol in serum. Curr Ther Res 1985;34:999-1008.
21. Leysen J: Receptors for antipsychotic drugs. Adv Hum Psychopharmacol. 1983;3:62-84.
22. Jenner P, Marsden CD: The substituted benzamides: A novel class of dopamine antagonists. Life Sci 1979;25:479-486.
23. Jenner P, Testa B, van de Waterbeem H, Marsden CD: Interaction of substituted benzamide drugs with cerebral dopamine receptors, in Ackenheil M, Matussek N (eds): Special Aspects of Psychopharmacology. Paris, Expansion Scientific Francaise, 1983, pp 153-170.
24. Köhler C, Hall H, Ögren S-O, Gawell L: Specific in vitro and in vivo binding of 3H-raclopride: A potent substituted benzamide drug with high affinity for dopamine D2 receptors in the rat brain. Biochem Pharmacol 1985;34:2251-2259.
25. Owen F, Cross AJ, Waddington JL: Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months' haloperidol administration. Life Sci 1980;26:55-59.
26. Burt DR, Creese I, Snyder SH: Antischizophrenic drugs: Chronic treatment elevated dopamine receptor binding in brain. Science 1977;196:326-328.
27. Clow A, Theodorou A, Jenner P: Changes in rat striatal dopamine turnover and receptor activity during one year's neuroleptic administration. Eur J Pharmacol 1980;63:135-144.
28. Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH: Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 1982;39:991-997.
29. Stille G, Hippius H: Kritische Stellungsnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatry 1971;4:182-191.
30. Borison RL, Hitri A, Blowers AJ, Diamond BI: Antipsychotic drug action: Clinical, biochemical, and pharmacological evidence for site specificity of action. Clin Neuropharmacol 1983;6:137-150.
31. Wiesel F-A, Bjerkenstedt L, Christensson E, Sedvall G: Melperone: An atypical neuroleptic compound of the butyrophenone type. Clinical Neuropharmacol 1986;9(suppl 4):314-315.
32. Fuxe K, Ögren S-O, Fredholm B, Agnati A, Hökfelt T, Perez de la Mora M: Possibilities of a differential blockade of central monoamine receptors. Read before Rhinencephale neurotransmetteurs et Psychoses, Symposium Bel-Air, Geneva, Switzerland, September 1976.
33. Michaelis L, Menten ML: Die Kinetik der Invertinwirkung. Biochem Z 1913;49:1333.
34. Clark AJ: The Mode of Action of Drugs on Cells. London, E Arnold Ltd, 1937.
35. Forsman A: Individual Differences in Clinical Response to an Antipsychotic Drug, thesis. Gothenburg, Sweden, University of Gothenburg, 1977.
36. Wode-Helgodt B, Borg S, Fyrö B, Sedvall G: Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 1978;58:149-173.
37. Baldessarini RJ, Davis JM: What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 1980;3:115-122.
38. Alfredsson G, Bjerkenstedt L, Edman G, Härnryd C, Oxenstierna G, Sedvall G, Wiesel F-A: Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. Acta Psychiatr Scand 1984;69(suppl 311):49-74.
39. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, May PRA: Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025-1029.
40. Bigelow LB, Kirch DG, Braun T, Korpi ED, Wagner RL, Zalcman S, Wyatt RJ: Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: A fixed-dose study. Psychopharmacol Bull 1985;21:66-68.